Anticoagulación en fibrilación auricularbre del 2015

Roberto Enrique López Mata

Resumen


Siempre se debe poner en perspectiva la relación riesgo beneficio acerca de qué terapia de anticoagulación es la más propicia para un paciente con fibrilación auricular, tanto para evitar un trombo embolismo así como un sangrado masivo. Esta revisión da un razonamiento clínico acerca de cuál es la mejor terapia según sea el caso.

Texto completo:

PDF

Referencias


Abbott RD, et al; Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018–1022.

BM Jones, Wang TJ, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042– 1046

Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140:886–890.

Cabbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983–988

Casinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35:183–187.

Connolly SJ, GoldMR, etal; ASSERT Investigators.Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120–129.

Dalpert JS,etal. 2014 AHA/ACC/ HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071–2104.

Dane CA, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263–272.

Feinberg WM, Hart RG. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. Neurology 20033; 43:32–36.

Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 20044; 154:1449–1457.

Fusuf S, etal; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–1151.

Garg J, etal; ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883–891.

Granger CB, McMurray JJ, etal; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–992.

Glund, Stephan, Ph.D; Idarucizuman for dabigatran reversal. N Engl J Med 2015;373;6

Kaatz, Scott; Kong, David; et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015; 373;9


Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2018 Revista Médica de Costa Rica y Centroamérica



Dirección OAI:

http://www.revistamedicacr.com/index.php/rmcr/oai/

Todos los derechos reservados. Se prohibe la reproducción total o parcial.

Revista Médica de Costa Rica 2021. ISSN:22155201